Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. decreased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,065,050 shares of the biotechnology company's stock after selling 210,665 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 7.62% of Arcturus Therapeutics worth $35,044,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Franklin Resources Inc. grew its stake in shares of Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock worth $2,412,000 after acquiring an additional 36,714 shares during the last quarter. Empire Life Investments Inc. acquired a new stake in shares of Arcturus Therapeutics in the third quarter worth $3,498,000. Hennion & Walsh Asset Management Inc. lifted its position in Arcturus Therapeutics by 139.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company's stock worth $1,393,000 after purchasing an additional 47,824 shares during the period. SG Americas Securities LLC bought a new position in Arcturus Therapeutics in the third quarter worth $191,000. Finally, Spire Wealth Management lifted its position in Arcturus Therapeutics by 393.3% in the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 10,746 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on ARCT. BTIG Research began coverage on Arcturus Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $41.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $65.00.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ ARCT traded up $1.64 during midday trading on Friday, reaching $18.05. 842,108 shares of the company traded hands, compared to its average volume of 362,393. The firm has a market cap of $488.97 million, a PE ratio of -8.13 and a beta of 2.62. The stock's 50-day simple moving average is $17.01 and its 200-day simple moving average is $18.95. Arcturus Therapeutics Holdings Inc. has a 12 month low of $14.30 and a 12 month high of $45.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.